DSI
FPRX

Daiwa SB Investments’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Daiwa SB Investments’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,700
Closed -$142K – 256
2017
Q2 		$142K Sell
4,700
-975
-17% -$30.4K 0.04% 140
2017
Q1 		$205K Sell
5,675
-565
-9% -$24.9K 0.06% 125
2016
Q4 		$313K Sell
6,240
-1,260
-17% -$66.2K 0.08% 112
2016
Q3 		$394K Buy
+7,500
New +$358K 0.1% 114

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Daiwa SB Investments's FPRX Position: Q3 2017 in Review

Daiwa SB Investments sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2017, closing a stake of 4,700 shares — an estimated $142K sold.

Daiwa SB Investments first reported a position in FPRX in Q3 2016 and held it in 4 quarters. The position peaked at $394K in Q3 2016. 126 funds tracked by Wall St. Rank hold FPRX as of Q3 2017.

  • Daiwa SB Investments reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Daiwa SB Investments sold 4,700 Five Prime Therapeutics, Inc. shares in Q3 2017, an estimated $142K.
  • Daiwa SB Investments first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 4 quarters.
  • Daiwa SB Investments's Five Prime Therapeutics, Inc. position peaked at $394K in Q3 2016.
  • 126 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2017.

Based on Daiwa SB Investments's 13F filing for Q3 2017, filed 13 Oct 2017.